ASCLS eNewsBytes

• Next-Gen AI-powered Coronary Imaging Platform Receives FDA Clearance, CE Mark June 9, 2026
  Abbott has obtained FDA clearance and CE Mark for its Ultreon 3.0 software, integrating coronary imaging and AI-automated insights to enhance patient outcomes and minimize risks.
• Scientists in 'Autonomous Laboratories' Are Starting to Outsource Work to Robots June 9, 2026
  Robots in the lab engage in distinct science projects, resembling one-armed machines encased in glass. A large screen displays a color-coded schedule of their tasks, while a track delivers equipment between them, similar to a toy train set.
• How Breast Cancer Screening Can Predict Heart Disease Risk June 9, 2026
  Mammograms, essential for breast cancer detection, can also be used with artificial intelligence to assess heart disease risk. Researchers created an AI model that analyzes mammograms to measure calcium buildup in breast arteries, known as breast arterial calcifications.
• AI Uses Everyday Language to Make Genetic Diagnosis Easier June 9, 2026
  A new tool, MARRVEL-MCP, assists researchers in efficiently reaching genetic diagnoses by analyzing extensive genetic and biological data using accessible language.
• FDA Approves Interchangeable Insulin Glargine-Aldy for Type 1 and Type 2 Diabetes June 9, 2026
  The FDA has approved insulin glargine-aldy as an interchangeable biosimilar to insulin glargine for adults and pediatric patients with Type 1 diabetes and adults with Type 2 diabetes.